BioCentury | Oct 24, 2019

Combined PTP-1B and PTPN2 inhibition for weight loss in obesity

...II testing for Type II diabetes. NeuBase Therapeutics Inc. (NASDAQ:NBSE), Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Jun 26, 2019
Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

...Phase II testing for Type II diabetes. Ohr Pharmaceutical Inc., Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

...trodusquemine in additional animal models of AD. Ohr Pharmaceutical Inc., Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a...
BioCentury | Apr 3, 2015
Company News

Cold Spring Harbor, North Shore-LIJ form cancer partnership

...therapies tested at the new unit. Last year, CSHL and Ohr Pharmaceutical Inc. (NASDAQ:OHRP) formed DepYmed Inc....
BioCentury | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

...The partners established DepYmed Inc., a JV to develop Ohr's trodusquemine and related analogs for an undisclosed...
Items per page:
1 - 6 of 6
BioCentury | Oct 24, 2019

Combined PTP-1B and PTPN2 inhibition for weight loss in obesity

...II testing for Type II diabetes. NeuBase Therapeutics Inc. (NASDAQ:NBSE), Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Jun 26, 2019
Distillery Therapeutics

Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes

...Phase II testing for Type II diabetes. Ohr Pharmaceutical Inc., Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Feb 28, 2019
Distillery Therapeutics

Neurology

...trodusquemine in additional animal models of AD. Ohr Pharmaceutical Inc., Cold Spring Harbor Laboratory and DepYmed Inc....
BioCentury | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a...
BioCentury | Apr 3, 2015
Company News

Cold Spring Harbor, North Shore-LIJ form cancer partnership

...therapies tested at the new unit. Last year, CSHL and Ohr Pharmaceutical Inc. (NASDAQ:OHRP) formed DepYmed Inc....
BioCentury | Mar 10, 2014
Company News

Ohr, Cold Spring Harbor Laboratory deal

...The partners established DepYmed Inc., a JV to develop Ohr's trodusquemine and related analogs for an undisclosed...
Items per page:
1 - 6 of 6